Current Colorectal Cancer Reports

, Volume 6, Issue 4, pp 199–205

Management Strategies for Patients with KRAS Mutations

Authors

    • Gastrointestinal Malignancies and Developmental Therapeutics Program, Division of Medical OncologyUniversity of Colorado Cancer Center
  • S. Gail Eckhardt
    • Gastrointestinal Malignancies and Developmental Therapeutics Program, Division of Medical OncologyUniversity of Colorado Cancer Center
  • Wells A. Messersmith
    • Gastrointestinal Malignancies and Developmental Therapeutics Program, Division of Medical OncologyUniversity of Colorado Cancer Center
Article

DOI: 10.1007/s11888-010-0066-x

Cite this article as:
Leong, S., Eckhardt, S.G. & Messersmith, W.A. Curr Colorectal Cancer Rep (2010) 6: 199. doi:10.1007/s11888-010-0066-x
  • 35 Views

Abstract

In an era of targeted therapies and personalized medicine, the search for predictive and prognostic biomarkers has reached the forefront in cancer research. Testing for KRAS mutation status in the treatment of colorectal cancer (CRC) has now become standard of care, especially for patients being considered for treatment with antibodies to the epidermal growth factor receptor (EGFR). Because metastatic CRC patients whose tumors harbor KRAS mutations do not respond to EGFR-targeting antibodies, their management is challenging. As our understanding of the role of KRAS mutations grows, new treatment strategies are being devised but are not yet ready for clinical use. In this review, we examine some of these potential strategies.

Keywords

KRASKRAS mutationsColorectal cancerNovel therapeutics

Copyright information

© Springer Science+Business Media, LLC 2010